Cargando…
In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
Blockade of the programmed cell death protein 1 (PD1) pathway is clinically effective against human cancers. Although multiple types of malignancies have been shown to respond to PD1 agents, only a small percentage of patients typically benefit from this treatment. In addition, PD1 therapy often cau...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443360/ https://www.ncbi.nlm.nih.gov/pubmed/28546884 http://dx.doi.org/10.1186/s40164-017-0075-4 |